Lack of Cost-sharing Subsidies Reduces TKI Initiation and Adherence in CML

Share this content:
Disparities of cost-sharing subsidies among Medicare beneficiaries with chronic myeloid leukemia may reduce adherence to TKI therapy.
Disparities of cost-sharing subsidies among Medicare beneficiaries with chronic myeloid leukemia may reduce adherence to TKI therapy.

Disparities of cost-sharing subsidies among Medicare beneficiaries with chronic myeloid leukemia (CML) may reduce adherence to tyrosine kinase inhibitor (TKI) therapy, according to a study published in the Journal of Clinical Oncology.1

TKIs have dramatically increased the life expectancy among patients with CML. For some patients, however, these drugs are prohibitively expensive, which can lead to a delay in treatment initiation. High prescription costs may also reduce adherence; both low adherence and delays in treatment initiation are both linked to worse survival.

Researchers enrolled 393 patients at least 66 years old (one must be at least 65 to enroll in Medicare) who were diagnosed with CML between 2007 and 2011. Only 68.2% of patients initiated TKI therapy within 6 months of diagnosis; only 61% of those who initiated TKI therapy were adherent for 6 months after initiating therapy.

Living in a large metropolitan area and being younger than 70 raised the likelihood of TKI initiation; those older than 80 were also less likely to adhere to medication regimens than those younger than 70. Patients with cost-sharing subsidies were likely to initiate therapy sooner than those without.

RELATED: Disparities in Childhood CML Outcomes Persist Among Some European Countries and the US

The authors conclude that there are gaps in TKI initiation and adherence among Medicare-enrolled patients with CML. Patients without cost-sharing subsidies may pay almost $3000 for the first month of TKI therapy, followed by $550 per month for the rest of the year. These high costs may lead to earlier mortality due to suboptimal rates of drug initiation and adherence.

Reference

  1. Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016 Oct 3. doi: 10.1200/JCO.2016.67.4184 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs